US President Donald Trump signed an executive order on August 10 recognizing an 11-disease core childhood immunization list and calling for separate measles, mumps and rubella shots. Separate products are not currently available in the United States, while state school mandates do not change automatically.

The order revives much of a January overhaul that a federal judge stayed in March. It also directs the US health secretary to submit plans within 90 days on vaccine timing, single-disease products and safety monitoring, leaving several implementation questions unresolved.

The order divides immunizations into three groups

A clinician and patient discuss a medical chart in an examination room (illustrative image)

The executive order lists immunizations against 11 diseases for all children: measles, mumps, rubella, diphtheria, tetanus, pertussis, polio, Haemophilus influenzae type B, pneumococcal disease, human papillomavirus and varicella. The White House compares that list with 17 vaccine-preventable diseases plus a respiratory syncytial virus (RSV) monoclonal antibody in the 2024 federal schedule, which it counts as 18.

A second category covers children in specified higher-risk groups and includes RSV monoclonal antibodies, hepatitis A, hepatitis B, two meningococcal vaccine groups and dengue. A third category places hepatitis A, hepatitis B, rotavirus, meningococcal disease, influenza and COVID-19 under shared clinical decision-making. Hepatitis A and B appear in both categories because the applicable route depends on a child's circumstances.

The order calls for the combined measles, mumps and rubella (MMR) vaccine to be replaced by three single-disease shots once those products are available domestically. It also recommends separate appointments for all childhood immunizations whenever feasible. The health secretary must present a plan within 90 days, and the order says combination vaccines should remain available.

The Associated Press reported that no separate measles, mumps and rubella products are currently available for children in the United States. The order does not set a date for such products to reach the market.

State requirements and a federal schedule are different systems

US states, rather than the federal government, set vaccination requirements for school attendance. The order advises states and territories to consider revising their laws; it does not itself amend them. Federal recommendations can still influence clinical practice, insurance coverage and vaccine supply, which makes the status of the earlier schedule dispute important.

A US District Court judge on March 16 stayed a January 2026 memorandum revising the childhood schedule, the appointments of 13 members of the Advisory Committee on Immunization Practices and all votes taken by that panel. The judge found that the plaintiffs were likely to succeed in showing that officials bypassed required procedures, including the committee's established role, but the ruling was preliminary rather than a final judgment.

The administration appealed the March ruling to the US Court of Appeals for the First Circuit, where the case remained pending before the August order. The new order declares a presidential policy and directs federal agencies to take steps within their legal authority. Its practical effect will depend on agency action, the existing court order and any further litigation; APPI News could not find a published ruling that had addressed the August 10 order at the time of writing.

Medical groups retain a broader 2026 schedule

The American Academy of Pediatrics (AAP) published its own 2026 schedule after withdrawing endorsement of the federal version. It retains routine or risk-based recommendations across a broader set of diseases, including influenza, hepatitis A, hepatitis B, rotavirus and RSV immunization.

Trump and US Health Secretary Robert F. Kennedy Jr. have repeatedly suggested that childhood vaccination may be connected to autism diagnoses. The August order does not make autism a formal finding, but Trump raised the claim while signing it.

A World Health Organization expert committee reviewed 31 primary studies published from 2010 through August 2025 and found no causal link between vaccines and autism spectrum disorder. Its conclusion covered vaccines generally and evidence on thiomersal and aluminum-containing products.

Two large cohort studies cited in the debate reached the same result. A 2019 Danish study followed 657,461 children and found no increased autism risk associated with MMR vaccination. A 2015 US study of 95,727 children found no association between MMR vaccination and autism, including among children with an older sibling diagnosed with autism.

More visits can affect completion

The White House says separate products and visits would expand parental choice. The available evidence on completion points to a tradeoff: adding appointments creates more opportunities for a series to remain unfinished.

A peer-reviewed study using the 2012 US National Immunization Survey found that 69 percent of children who received at least one combination vaccine completed the full series by age two, compared with 50 percent of children who received only single-antigen products. Timely compliance was 24 percent and 13 percent, respectively. The study was observational and funded by vaccine manufacturer GlaxoSmithKline, which participated in its design, analysis and interpretation.

Japan's experience includes a wider policy change

Japan ended routine use of its MMR vaccine in 1993 after cases of aseptic meningitis associated with the mumps strain then used in the product. Measles and rubella vaccination remained part of the routine program, while mumps vaccination continued separately on a voluntary basis.

Japan's National Institute of Infectious Diseases later estimated mumps vaccination coverage at about one-third of measles coverage and documented renewed mumps outbreaks after the MMR program ended. The same report cited a 2001 national survey estimating that 650 people received care for acute complete deafness caused by mumps infection.

That record illustrates the coverage risk when one component falls outside a routine program, but it is not a controlled comparison of combined and separate injections. Product safety concerns and recommendation status changed at the same time, so Japan's experience cannot establish what the US order will do.

What happens next

The first deadline is the health secretary's 90-day report to the president. It must address single-disease products, timing and sequencing, alternative adjuvants, safety studies and monitoring. Federal agencies must then decide what actions fall within their authority, while states decide whether to revisit school requirements.

Until those steps occur, the order remains a federal policy direction rather than a fully implemented vaccination schedule. The court case, the absence of separate US MMR products and the AAP's competing schedule leave families and clinicians with overlapping sources of guidance.

Frequently asked questions

Does the order immediately reduce every US child's recommended immunizations from 18 diseases to 11?
No. It recognizes an 11-disease federal core list and directs agencies to advance it, but implementation remains subject to agency authority, a federal court order and state law.

Are separate measles, mumps and rubella shots available in the United States?
No separate pediatric products are currently available in the United States. The order calls for a plan to make them available while keeping combination vaccines on the market.

What does the evidence say about vaccines and autism?
The WHO's 2025 review of 31 primary studies found no causal link. Large cohort studies in Denmark and the United States also found no increased autism risk associated with MMR vaccination.